Insulet Corporation PODD
Nov 5, 2026, 9:58 AM EST
- YTD
- -42.01%
- 1 year
- -47.58%
- Market cap
- 11.40B
- Revenue (ttm)
- 3.05B
- Profit margin
- 12.29%
- EPS (ttm)
- 6.12
- Shares out
- 69.35M
- P/E ratio
- 26.86
- Forward P/E
- 21.37
- YTD return
- -42.01%
- 1-year return
- -47.58%
- Volume
- 72.52K
- Avg volume
- 1.63M
- Open
- 167.33
- Previous close
- 165.02
- Day's range
- 163.36 – 168.34
- 52-week range
- 130.47 – 346.36
- Beta
- 1.05
- Analysts
- Buy
- Price target
- 167.17 (+1.4%)
- Earnings date
- Feb 17, 2027
5D +10.34 (+6.71%)
Key statistics
- Enterprise value
- 11.22B
- PEG ratio
- 1.22
- Price / sales
- 3.75
- Price / book
- 8.05
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 23.50%
- Free cash flow
- 236.90M
- Total cash
- 534.90M
- Total debt
- 1.02B
- Return on equity
- 26.02%
- Short % of float
- 9.16%
- 50-day average
- 141.21
- 200-day average
- 177.47
Analyst view
Consensus: buy
- Target (low)
- 143.00
- Target (mean)
- 167.17
- Target (high)
- 215.00
- Strong buy4
- Buy11
- Hold11
- Sell0
- Strong sell0
Next earnings
Feb 17, 2027
Expected Feb 17, 2027. Consensus EPS estimate 1.85.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 17, 2027 | Dec 30, 2026 | 1.85 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | 1.59 | 1.99 | +0.40 | +25.16% |
| Aug 5, 2026 | Jun 30, 2026 | 1.47 | 1.66 | +0.19 | +12.93% |
| May 6, 2026 | Mar 31, 2026 | 1.19 | 1.42 | +0.23 | +19.33% |
| Feb 18, 2026 | Dec 31, 2025 | 1.47 | 1.55 | +0.08 | +5.44% |
| Nov 6, 2025 | Sep 30, 2025 | 1.14 | 1.24 | +0.10 | +8.77% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | Jefferies | main | Buy | Buy |
| Oct 7, 2026 | Barclays | init | — | Equal-Weight |
| Aug 6, 2026 | Canaccord Genuity | main | Buy | Buy |
| Aug 6, 2026 | Leerink Partners | down | Outperform | Market Perform |
| Aug 6, 2026 | TD Cowen | main | Hold | Hold |
| Aug 6, 2026 | UBS | main | Neutral | Neutral |
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- insulet.com
News
Insulet CEO Sees Slower Growth in 2027, Expects Rivals to Chip Away at Omnipod's Market Share 
What Insulet (PODD) Said on Its Q3 Earnings Call 
Insulet Corporation (PODD) Q3 2026 Earnings Call Transcript 
Insulet (PODD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates 
Insulet (PODD) Q3 Earnings and Revenues Surpass Estimates 
Insulet Q3 2026 Earnings Call Transcript 
Insulet FY2026 Adj EPS expected to be more than $6.46 vs $6.46 Est; Raises FY2026 Sales Guidance from $3.250B-$3.304B to $3.277B-$3.304B vs $3.289B Est 
Insulet Q3 Adj. EPS $1.99 Beats $1.59 Estimate, Sales $842.000M Beat $832.685M Estimate 
Insulet Reports Third Quarter 2026 Results 
Insulet to Participate in the 2026 Jefferies Global Healthcare Conference in London
Your note
Sign in to keep a note on PODD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BENJAMIN ERIC | Chief Operating Officer | Stock Award(Grant) | Feb 23, 2026 | 24,512 |
| CHADWICK ANA MARIA | Chief Financial Officer | Stock Award(Grant) | Feb 24, 2025 | 16,028 |
| FIELD MARK N | Chief Technology Officer | Stock Award(Grant) | Feb 24, 2025 | 13,915 |
| HOLLINGSHEAD JAMES R | Chief Executive Officer | Stock Award(Grant) | Feb 24, 2025 | 68,068 |
| HOPFIELD JESSICA | Director | Stock Award(Grant) | May 19, 2026 | 29,355 |
| KAPPLES JOHN W. | General Counsel | Stock Award(Grant) | Feb 23, 2026 | 28,119 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.65% | 6,690,192 | 1.10B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.52% | 4,525,333 | 746.77M | Jun 29, 2026 |
| State Street Corporation | 4.61% | 3,197,555 | 527.66M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.44% | 3,075,932 | 507.59M | Jun 29, 2026 |
| AQR Capital Management, LLC | 3.54% | 2,455,135 | 405.15M | Jun 29, 2026 |
| BAILLIE GIFFORD & CO | 2.94% | 2,042,313 | 337.02M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 2,199,429 | 362.95M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.59% | 1,792,909 | 295.87M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.29% | 1,589,038 | 262.22M | Jun 29, 2026 |
| Invesco Exchange-Traded Fund Trust-Invesco S&P 500 Equal Weight ETF | 2.05% | 1,418,299 | 234.05M | Sep 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 925,214 | 152.68M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.32% | 916,226 | 151.20M | Jun 29, 2026 |